News Drug Formulary Safety Net Resources
Drug Formulary Categories and Charges Search HA Drug Formulary Self-financed Drugs Available for Purchase by Patients at HA Pharmacy How we evaluate new drugs Governance Drug Management Committee Drug Advisory Committee Drug Formulary Committee Drug & Therapeutics Committee Drug Selection Committee Expert Panel Medication Safety Committee Samaritan Fund Community Care Fund Drug Education HA Drug Formulary Management Manual Frequently Asked Questions Useful Links
HA Drug Formulary
Version 21.4 – with effect from 25 April 2026
  1. The drugs may either be listed as generic or proprietary names, where appropriate. Brand names listed serve as reference only, they do not necessarily indicate the availability of that particular brand.
  2. Some drugs may appear in more than one category due to different formulations and/or indications.
  3. The "Special" drugs will be prescribed as clinically indicated based on the specified indications.
  4. Based on operational logistics and needs, individual cluster/hospital may only stock part of the drugs listed on the HA Drug Formulary.
Special Programmes for use of drugs on Individual Patient
AGALSIDASE ALFA
AGALSIDASE BETA
ALGLUCOSIDASE ALFA
AVALGLUCOSIDASE ALFA
BUROSUMAB
CARGLUMIC ACID
DINUTUXIMAB BETA
ECULIZUMAB
ELOSULFASE ALFA
GALSULFASE
IDURSULFASE
IMIGLUCERASE
IPTACOPAN
LARONIDASE
MIGALASTAT
NUSINERSEN
ONASEMNOGENE ABEPARVOVEC
RAVULIZUMAB
RISDIPLAM
TAFAMIDIS MEGLUMINE
TISAGENLECLEUCEL
VELMANASE ALFA